Research Use Only. The information presented here is for scientific and educational purposes. These compounds are not intended for human consumption, self-administration, or therapeutic use.
Introduction
The term glp 2 peptide is used two ways in the research literature, and the distinction matters before any experiment is designed. In classical endocrinology, GLP-2 is the native 33-amino acid proglucagon product released by intestinal L-cells that signals through its own receptor, GLP-2R. In the coded research catalog, GLP-2 TZ is something else: a 39-amino acid synthetic peptide engineered to activate two incretin receptors at once, the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). The “2” refers to the number of receptors engaged, not to the native GLP-2 hormone.
This article covers the second meaning: the dual-agonist pharmacology that makes GLP-2 TZ a distinct research tool. It examines the two receptors, why combining them produces signaling neither achieves alone, how the peptide is engineered for stability, and what preclinical models measure. Every observation below comes from in-vitro assays and animal studies, supplied for research use only, not for human consumption.
The Two Receptors Behind Dual Agonism
GLP-1R
The GLP-1 receptor is a class B1 G-protein-coupled receptor in the glucagon receptor superfamily. Its native ligands, GLP-1 (7-36 amide) and GLP-1 (7-37), are released by intestinal L-cells. Receptor occupancy couples primarily to Gs, activating adenylate cyclase and raising intracellular cyclic AMP (cAMP), with downstream engagement of protein kinase A and EPAC2. In cultured beta-cell lines the receptor also recruits Gq, adding a calcium-mobilizing arm that GIPR signaling largely lacks. GLP-1R is expressed in pancreatic islets, the central nervous system, the gut, and cardiac tissue in the species used to map it.
GIPR
The GIP receptor is the second incretin receptor and also a class B1 GPCR. Its native ligand, glucose-dependent insulinotropic polypeptide, is a 42-amino acid peptide secreted by duodenal K-cells. GIPR couples selectively to Gs in beta-cell models, producing a cAMP response without the parallel Gq arm. Its expression pattern makes it interesting as a second target: beyond islets, GIPR appears in adipose tissue (adipocytes, endothelial cells, pericytes), in bone, and in discrete brain regions including the hypothalamic arcuate nucleus and hindbrain, where 2025 reviews report expression concentrated in GABAergic neurons distinct from those bearing GLP-1R.
The values below reflect commonly reported laboratory attributes and are provided for comparison only.
| Attribute | GLP-1R | GIPR |
|---|---|---|
| Receptor class | Class B1 GPCR | Class B1 GPCR |
| Native ligand | GLP-1 (7-36 amide / 7-37) | GIP (1-42) |
| Native ligand length | 30 to 31 amino acids | 42 amino acids |
| Principal G-protein coupling | Gs, with Gq in some cell models | Gs (selective in beta-cell models) |
| Second messenger | cAMP | cAMP |
| Expression in model systems | Islets, CNS, gut, heart | Islets, adipose tissue, bone, discrete brain nuclei |
What the GLP-2 Peptide Is: Molecular Identity of GLP-2 TZ
Sequence and Engineering
GLP-2 TZ is a synthetic 39-residue peptide built on a GIP-based backbone carrying substitutions drawn from GLP-1, which is how one chain achieves measurable affinity at two receptors that recognize different native hormones. Published characterizations of this design describe roughly two-thirds sequence homology with GIP and about half with GLP-1. Two engineering features are standard. The first is a non-coded residue at position 2, typically 2-aminoisobutyric acid (Aib), which blocks cleavage by dipeptidyl peptidase-4 (DPP-4), the enzyme that inactivates both native incretins within minutes. The second is fatty-acid acylation at a lysine side chain, which promotes reversible albumin binding and extends the circulating window in animal models from minutes to days.
The values below reflect commonly reported laboratory attributes and are provided for comparison only.
| Attribute | Reported value |
|---|---|
| Designation | GLP-2 TZ |
| Class | Unimolecular dual-receptor incretin agonist |
| Receptor targets | GIPR and GLP-1R |
| Sequence length | 39 amino acids |
| Approximate molecular weight | About 4814 Da (roughly 4.8 kDa) |
| Backbone | GIP-based scaffold with GLP-1 substitutions |
| Stability motifs | Aib at position 2 (DPP-4 resistance); fatty-acid acylation (albumin binding) |
Distinguishing It From Native GLP-2
Because searches for the glp 2 peptide return both meanings, the separation is worth making explicit. Native GLP-2 is 33 amino acids, weighs about 3.75 kDa, and acts on GLP-2R, a receptor found on subepithelial myofibroblasts and enteric neurons rather than on absorptive enterocytes; its literature concerns intestinal barrier and mucosal endpoints. The dual-agonist compound described here shares neither the receptor nor the sequence with it.
Why Dual GIP/GLP-1 Receptor Agonism Is Studied
Complementary Signaling Arms
The central research question in this class is whether engaging both incretin receptors produces effects that mono-agonism does not. Work published through 2025 and 2026 has separated the two arms. GIPR agonism in rodent models is associated with nutrient handling in adipose tissue, including lipoprotein lipase activity, adipocyte insulin sensitivity, and branched-chain amino acid catabolism, endpoints GLP-1R agonism does not reproduce, and reports describe GIPR activation engaging calcium cycling in white adipose tissue as a route to altered energy expenditure. GLP-1R agonism, in contrast, dominates glucose-dependent insulinotropic signaling in islet preparations.
Separable Central Circuits
A 2025 line of work in mice used receptor-deletion models to show the two receptors act through genuinely different neuronal populations. GIPR agonism reduced food intake through GABAergic neurons and retained its effect in animals lacking GLP-1R, while receptor blockade at GIPR produced a superficially similar outcome that disappeared when GLP-1R signaling was removed. Transcriptional profiling of the dorsal vagal complex found that GIPR agonism and antagonism moved synaptic-plasticity genes in opposing directions. This work, labeled the GIPR paradox in reviews, is why dual agonists are studied as tools for dissecting circuits rather than as a simple additive combination.
Biased Agonism
A further variable is signaling bias. Class B GPCRs recruit beta-arrestin alongside G proteins, and arrestin recruitment drives receptor internalization and desensitization. Studies published in 2025 examined dual GLP-1R and GIPR peptides engineered to favor cAMP generation over arrestin recruitment, reporting in cell assays and rodent models that the biased profile altered how long receptor signaling persisted at the surface. A dual agonist is therefore characterized on at least three axes: potency at each receptor, the ratio between them, and the G-protein-versus-arrestin balance at each.
Laboratory Readouts and Handling
Common Assay Endpoints
Characterization typically begins in cells expressing one receptor at a time, so activity at GIPR and GLP-1R can be separated. Standard readouts include cAMP accumulation assays for potency (EC50) at each receptor, beta-arrestin recruitment assays using complementation reporters, ligand binding for affinity, and confocal imaging of receptor internalization. Animal work adds glucose tolerance testing, islet perfusion, adipose gene expression, and food-intake measurement in receptor-knockout backgrounds where each contribution can be isolated. The same design logic extends to mono-agonists such as GLP-1 SM and to the triple-receptor peptide GLP-3 RT, which adds the glucagon receptor to the same two incretin targets.
Reconstitution and Documentation
GLP-2 TZ is supplied as a lyophilized powder. As a worked example, adding 2 mL of bacteriostatic water to a 10 mg vial yields a 5 mg/mL stock; the general procedure is covered in the bacteriostatic water reconstitution guide. Acylated peptides of this class are handled cold, protected from light, and aliquoted to avoid repeated freeze-thaw cycles. Because potency ratios are the entire point of a dual agonist, identity data matter more than usual: mass spectrometry confirms the acylation and the position-2 substitution are present, and HPLC quantifies purity. Reading those figures is covered in the COA and purity guide, with lot documentation on the certificates page and related compounds in the research peptide catalog.
Frequently Asked Questions
What is the GLP-2 peptide in the coded research series?
In the coded catalog, GLP-2 TZ is a synthetic 39-amino acid peptide that activates two incretin receptors, GIPR and GLP-1R. The number refers to the count of receptors engaged rather than to the native GLP-2 hormone, which is a separate 33-amino acid proglucagon product acting on its own GLP-2 receptor.
What does dual GIP/GLP-1 receptor agonism mean?
It means one peptide sequence carries enough structural information to bind and activate both the GIP receptor and the GLP-1 receptor. Both are class B1 G-protein-coupled receptors that raise intracellular cAMP, but they are expressed on different tissues and, in rodent studies, act through different neuronal populations.
How is GLP-2 TZ different from native GLP-2?
They share a naming convention and nothing else. Native GLP-2 is 33 amino acids, weighs about 3.75 kDa, and signals through GLP-2R on subepithelial myofibroblasts and enteric neurons. GLP-2 TZ is 39 amino acids, weighs about 4.8 kDa, and signals through GIPR and GLP-1R.
Why do researchers combine GIP and GLP-1 receptor activity?
Because the two receptors govern partly separate biology in preclinical models. GIPR activity is associated with adipose nutrient handling and distinct central circuits, while GLP-1R activity dominates glucose-dependent insulinotropic signaling in islets. Engaging both allows investigators to study interactions that neither mono-agonist reproduces.
What is the molecular weight of GLP-2 TZ?
Reported characterizations place it near 4814 Da, roughly 4.8 kDa, for a 39-residue acylated peptide. The exact mass varies with the specific acyl chain and substitutions and is confirmed by mass spectrometry on the batch certificate of analysis.
Is GLP-2 TZ intended for any use outside the laboratory?
No. It is a research compound characterized in cell assays and animal models. It is supplied for research use only, not for human consumption, self-administration, or therapeutic use.
References and Further Reading
- Reviews of dual GIP and GLP-1 receptor agonist chemistry and receptor pharmacology. PubMed: dual GIP GLP-1 receptor agonist pharmacology
- Studies of GIP receptor expression and signaling in adipose tissue, islets, and brain in animal models. PubMed: GIP receptor adipose tissue signaling
- Work distinguishing the mechanisms of GIPR agonism from GIPR antagonism in mice, including GABAergic neuron dependence. PubMed: GIPR agonism antagonism food intake mice
- Reports on biased agonism at GLP-1R and GIPR, comparing cAMP generation with beta-arrestin recruitment. PubMed: GLP-1R GIPR biased agonism beta-arrestin
- Structural studies of the GIP receptor and hormone recognition by class B GPCRs. PubMed: GIP receptor structure class B GPCR
- Reviews of GIP physiology in health and disease models, including incretin biology. PubMed: glucose-dependent insulinotropic polypeptide incretin physiology
- Research on DPP-4 resistance and acylation strategies used to extend incretin peptide stability. PubMed: incretin analog DPP-4 resistance acylation half-life
